secwatch.observer — SEC 8-K summary
======================================

Issuer:     Canton Strategic Holdings, Inc. (CNTN)
CIK:        0001861657
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001493152-23-039743
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tharimmune licenses clinical-stage TH104 for chronic pruritis; PBC Phase 2 trial planned
--------------------------------------------------------------------------------

- Exclusive worldwide license from Avior for TH104 (AV104) and TH103; targets chronic pruritis in PBC, an orphan liver disease.
- Upfront mid-six-digit fee plus installments; up to $24.25M in development milestones plus sales-based payments and royalties.
- Plans to initiate Phase 2 trial in PBC patients within ~12 months after FDA alignment; expects top-line data thereafter.
- TH104 uses buccal film delivery with dual mechanism on μ-opioid and κ-opioid receptors and IL-17 inhibition.
- CEO Randy Milby says license agreement represents shift to clinical development focus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861657/000149315223039743/0001493152-23-039743-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861657/000149315223039743/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-039743

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer